This is a StreetInsider.com Premium Only Page

Adicet Bio (ACET) – Company Press Releases

Apr 8, 2024 07:00 AM Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 28, 2024 05:19 PM Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Mar 19, 2024 04:10 PM Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

Mar 11, 2024 07:00 AM Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Feb 29, 2024 07:46 PM Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Feb 5, 2024 04:01 PM Adicet Bio to Participate in a Fireside Chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Jan 31, 2024 04:39 PM Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Jan 25, 2024 04:01 PM Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

Jan 22, 2024 11:43 PM Adicet Bio, Inc. Announces Pricing of Public Offering

Jan 22, 2024 04:28 PM Adicet Bio, Inc. Announces Proposed Public Offering

Jan 4, 2024 07:00 AM Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024

Jan 3, 2024 04:01 PM Adicet Bio to Host Conference Call to Provide Updates on its Clinical Pipeline and Corporate Outlook

Dec 29, 2023 04:50 PM Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Dec 10, 2023 12:00 PM Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology (ASH) Annual Meeting

Nov 8, 2023 04:10 PM Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 7, 2023 07:00 AM Adicet Bio to Present at the 2023 Jefferies London Healthcare Conference

Nov 2, 2023 09:00 AM Adicet Bio Announces Poster Presentation Highlighting ADI-001 Data at the 65th American Society of Hematology (ASH) Annual Meeting

Oct 31, 2023 06:25 PM Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

Oct 4, 2023 12:00 PM Adicet Bio Announces Poster Presentation at the Upcoming 2023 Molecular Targets and Cancer Therapeutics Conference

Sep 29, 2023 05:24 PM Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Sep 27, 2023 09:00 AM Adicet Bio to Present Three Scientific Posters Highlighting its Allogeneic Gamma Delta T Cell Platform and Programs at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

Aug 31, 2023 04:35 PM Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Aug 9, 2023 04:15 PM Adicet Reports Second Quarter 2023 Financial Results and Provides Business Updates

Aug 2, 2023 04:00 PM Adicet Bio to Participate in a Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference

Jul 31, 2023 04:50 PM Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jul 11, 2023 08:30 AM Adicet Announces Appointment of Katie Peng to the Board of Directors

Jun 30, 2023 04:51 PM Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jun 26, 2023 04:00 PM Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Jun 1, 2023 07:00 AM Adicet Bio to Participate in a Fireside Chat at the 2023 Jefferies Healthcare Conference

May 31, 2023 04:53 PM Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

May 18, 2023 06:00 AM Adicet Bio Presents Positive Preclinical Data on ADI-270 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting

May 9, 2023 04:30 PM Adicet Bio to Present at the 2023 JMP Securities Life Sciences Conference

May 9, 2023 04:10 PM Adicet Reports First Quarter 2023 Financial Results and Provides Business Updates

Apr 28, 2023 05:13 PM Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Apr 13, 2023 07:00 AM Adicet Bio to Participate in 2023 Canaccord Genuity Horizons in Oncology Virtual Conference

Mar 31, 2023 04:31 PM Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Mar 15, 2023 04:01 PM Adicet Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress

Mar 9, 2023 07:00 AM Adicet Bio to Participate in 2023 Jefferies Biotech on the Bay Summit

Feb 28, 2023 05:31 PM Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Feb 1, 2023 07:00 AM Adicet Bio to Participate in a Fireside Chat at the 2023 Guggenheim Oncology Conference

Jan 31, 2023 08:40 PM Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Dec 30, 2022 04:43 PM Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Dec 10, 2022 10:00 AM Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Dec 2, 2022 07:00 AM Adicet Bio to Host Investor Webcast to Discuss Updated Clinical Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

Nov 30, 2022 08:08 PM Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Nov 30, 2022 04:00 PM Adicet Bio to Present at the Virtual JMP Securities Hematology and Oncology Summit

Nov 29, 2022 07:00 AM Adicet Bio Appoints Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory Officer

Nov 8, 2022 04:10 PM Adicet Reports Third Quarter 2022 Financial Results and Provides Business Updates

Nov 7, 2022 08:00 AM Adicet Bio Showcases Preclinical Data for Four New Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Nov 3, 2022 09:00 AM Adicet Bio Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)